Risks of Using TRUE METRIX Blood Glucose Monitoring Systems by Trividia Health: FDA Safety Communication
The FDA issued a safety communication alerting users and healthcare providers to risks associated with TRUE METRIX Blood Glucose Monitoring Systems manufactured by Trividia Health.
This affects Trividia Health, healthcare providers, and regulatory or compliance professionals managing blood glucose monitoring systems or similar point-of-care diagnostic devices.
While the source provides limited detail on the specific clinical nature of the risks, an FDA safety communication typically indicates that post-market data or reported adverse events have reached a threshold requiring formal public notification. For regulatory teams, this signal may precede further enforcement actions, such as labeling changes or corrective and preventive actions (CAPA) regarding device accuracy or user interface risks.
Regulatory and QA teams should review internal safety signals related to these systems, ensure customer-facing documentation reflects current FDA warnings, and confirm that post-market surveillance protocols are effectively capturing relevant performance issues.
FDA alerts of risks with use TRUE METRIX Blood Glucose Monitoring Systems by Trividia Health.
Open in openFDA / FDA.gov